REFERENCES
1. Panebianco M, Marchese-Ragona R, Masiero S, Restivo DA. Dysphagia in neurological diseases: a literature review. Neurol Sci 2020;41:3067-73.
2. Warnecke T, Labeit B, Schroeder J, et al. Neurogenic dysphagia: systematic review and proposal of a classification system. Neurology 2021;96:e876-89.
3. Sura L, Madhavan A, Carnaby G, Crary MA. Dysphagia in the elderly: management and nutritional considerations. Clin Interv Aging 2012;7:287-98.
4. Wirth R, Dziewas R, Beck AM, et al. Oropharyngeal dysphagia in older persons - from pathophysiology to adequate intervention: a review and summary of an international expert meeting. Clin Interv Aging 2016;11:189-208.
5. Nascimento W, Tomsen N, Acedo S, et al. Effect of aging, gender and sensory stimulation of TRPV1 Receptors with capsaicin on spontaneous swallowing frequency in patients with oropharyngeal dysphagia: a proof-of-concept study. Diagnostics (Basel) 2021;11:461.
6. Dziewas R, Allescher HD, Aroyo I, et al. Diagnosis and treatment of neurogenic dysphagia - S1 guideline of the German society of neurology. Neurol Res Pract 2021;3:23.
7. Speyer R, Baijens L, Heijnen M, Zwijnenberg I. Effects of therapy in oropharyngeal dysphagia by speech and language therapists: a systematic review. Dysphagia 2010;25:40-65.
8. Warnecke T, Dziewas R, Langmore S. Neurogenic dysphagia. 1st ed. Cham: Springer, 2021.
11. Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: A case report and review of the literature. Ment Health Clin 2017;7:56-64.
12. Wolf U, Eckert S, Walter G, et al. Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs. Sci Rep 2021;11:21955.
13. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004;56:331-49.
14. Vidal P-P, Sans A. Chapter 30: Vestibular system. In: Paxinos G, editor. The rat nervous system, 3dr ed. London: Academic Press, 2004; pp. 965-96.
15. Tritsch NX, Sabatini BL. Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 2012;76:33-50.
16. Bieger D, Giles S, Hockman C. Dopaminergic influences on swallowing. Neuropharmacology 1977;16:245-52.
17. Jia YX, Sekizawa K, Ohrui T, Nakayama K, Sasaki H. Dopamine D1 receptor antagonist inhibits swallowing reflex in guinea pigs. Am J Physiol 1998;274:R76-80.
18. Gantois I, Fang K, Jiang L, et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci USA 2007;104:4182-7.
19. Park HY, Kim Y, Oh HM, Kim TW, Park GY, Im S. Potential prognostic impact of dopamine receptor d1 (. rs4532 ;12:675060.
20. Nimmons D, Pendleton N, Payton A, et al. A novel association between COMT and BDNF gene polymorphisms and likelihood of symptomatic dysphagia in older people. Neurogastroenterol Motil 2015;27:1223-31.
21. Warnecke T, Oelenberg S, Teismann I, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord 2010;25:1239-45.
22. Warnecke T, Suttrup I, Schröder JB, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test. Parkinsonism Relat Disord 2016;28:100-6.
23. Hunter PC, Crameri J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry 1997;63:579-83.
24. Hirano M, Isono C, Sakamoto H, Ueno S, Kusunoki S, Nakamura Y. Rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson’s disease. Dysphagia 2015;30:452-6.
25. Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, Kusunoki S. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson’s disease. J Neurol Sci 2019;404:5-10.
26. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996;11:729-32.
27. Michou E, Hamdy S, Harris M, et al. Characterization of corticobulbar pharyngeal neurophysiology in dysphagic patients with Parkinson’s disease. Clin Gastroenterol Hepatol 2014;12:2037-45.e1.
28. Chang MC, Park JS, Lee BJ, Park D. Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative review. Neurol Sci 2021;42:513-9.
29. Kobayashi H, Nakagawa T, Sekizawa K, Arai H, Sasaki H. Levodopa and swallowing reflex. Lancet 1996;348:1320-1.
30. Arai T, Sekizawa K, Yoshimi N, Toshima S, Fujiwara H. Cabergoline and silent aspiration in elderly patients with stroke. J Am Geriatr Soc 2003;51:1815-6.
31. Nakagawa T, Wada H, Sekizawa K, Arai H, Sasaki H. Amantadine and pneumonia. Lancet 1999;353:1157.
32. Apaydin H, Ertan S, Ozekmekçi S. Broad bean (Vicia faba) - A natural source ofL-dopa-Prolongs “on” periods in patients with Parkinson’s disease who have “on-off” fluctuations. Mov Disord 2000;15:164-6.
33. Kanazawa K, Sakakibara H. High content of dopamine, a strong antioxidant, in Cavendish banana. J Agric Food Chem 2000;48:844-8.
34. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep 2015;5:11078.
35. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75:1672-7.
36. Cacabelos R, Carrera I, Martínez O, et al. Atremorine in parkinson’s disease: from dopaminergic neuroprotection to pharmacogenomics. Med Res Rev 2021;41:2841-86.
37. Cacabelos R. World guide for drug use and pharmacogenomics. Corunna, Spain: EuroEspes Publishing Co., 2012.
38. Soler-Alfonso C, Motil KJ, Turk CL, et al. Potocki-Lupski syndrome: a microduplication syndrome associated with oropharyngeal dysphagia and failure to thrive. J Pediatr 2011;158:655-659.e2.
39. Michałowska M, Chalimoniuk M, Jówko E, et al. Gene polymorphisms and motor levodopa-induced complications in Parkinson’s disease. Brain Behav 2020;10:e01537.
40. Zhao C, Wang Y, Zhang B, Yue Y, Zhang J. Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson’s disease. Sci Rep 2020;10:9521.
41. Rieck M, Schumacher-Schuh AF, Callegari-Jacques SM, et al. Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson’s disease patients? Pharmacogenomics 2015;16:573-82.
42. Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients. Pharmacogenomics J 2014;14:289-94.
43. Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics 2012;13:1701-10.
44. Moreau C, Meguig S, Corvol JC, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain 2015;138:1271-83.
45. Ahmed SS, Husain RS, Kumar S, Ramakrishnan V. Association between MDR1 gene polymorphisms and Parkinson’s disease in Asian and Caucasian populations: a meta-analysis. J Neurol Sci 2016;368:255-62.
46. Lohr KM, Masoud ST, Salahpour A, Miller GW. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. Eur J Neurosci 2017;45:20-33.
47. Pouget JG, Shams TA, Tiwari AK, Müller DJ. Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci 2014;16:555-66.
48. Yoshida K, Müller DJ. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsychiatry 2020;5:1-26.
50. Kichko TI, Neuhuber W, Kobal G, Reeh PW. The roles of TRPV1, TRPA1 and TRPM8 channels in chemical and thermal sensitivity of the mouse oral mucosa. Eur J Neurosci 2018;47:201-10.
51. Alvarez-Berdugo D, Rofes L, Farré R, et al. Localization and expression of TRPV1 and TRPA1 in the human oropharynx and larynx. Neurogastroenterol Motil 2016;28:91-100.
52. Hossain MZ, Ando H, Unno S, Masuda Y, Kitagawa J. Activation of TRPV1 and TRPM8 channels in the larynx and associated laryngopharyngeal regions facilitates the swallowing reflex. Int J Mol Sci 2018;19:4113.
53. Peier AM, Moqrich A, Hergarden AC, et al. A TRP channel that senses cold stimuli and menthol. Cell 2002;108:705-15.
54. Alvarez-Berdugo D, Rofes L, Arreola V, Martin A, Molina L, Clavé P. A comparative study on the therapeutic effect of TRPV1, TRPA1, and TRPM8 agonists on swallowing dysfunction associated with aging and neurological diseases. Neurogastroenterol Motil 2018;30:e13185.
55. Cheng I, Sasegbon A, Hamdy S. Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis. Neurogastroenterol Motil 2022;34:e14220.
56. Snitker S, Fujishima Y, Shen H, et al. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. Am J Clin Nutr 2009;89:45-50.
57. Shamsi S, Tran H, Tan RS, Tan ZJ, Lim LY. Curcumin, piperine, and capsaicin: a comparative study of spice-mediated inhibition of human cytochrome P450 isozyme activities. Drug Metab Dispos 2017;45:49-55.
58. Don CG, Smieško M. In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants. Front. Pharmacol 2020;11:683.
59. Ikeda J, Kojima N, Saeki K, Ishihara M, Takayama M. Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia. Eur J Pharmacol 2015;746:126-31.
60. Shinohara Y, Origasa H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Adv Ther 2012;29:900-12.
61. Lee JS, Chui PY, Ma HM, et al. Does low dose angiotensin converting enzyme inhibitor prevent pneumonia in older people with neurologic dysphagia - a randomized placebo-controlled trial. J Am Med Dir Assoc 2015;16:702-7.
62. Chen D, Xing H, Jiang Q, Xiang Y, Hu W, Guo H. Role of levetiracetam in the rehabilitation of dysphagia due to stroke. Int J of Pharmacol 2017;13:603-11.
63. Monroe MD, Manco K, Bennett R, Huckabee M. Citric acid cough reflex test: Establishing normative data. J Speech Lang Hear 2014;17:216-24.
64. Fujiwara K, Kawamoto K, Shimizu Y, et al. A novel reflex cough testing device. BMC Pulm Med 2017;17:19.
65. Nurmi HM, Lätti AM, Brannan JD, Koskela HO. Comparison of mannitol and citric acid cough provocation tests. Respir Med 2019;158:14-20.
66. Krieger DW. Therapeutic drug approach to stimulate clinical recovery after Brain injury. Front Neurol Neurosci 2013:76-87.
67. Jayasekeran V, Pendleton N, Holland G, et al. Val66Met in brain-derived neurotrophic factor affects stimulus-induced plasticity in the human pharyngeal motor cortex. Gastroenterology 2011;141:827-836.e1.
68. Oh HM, Kim TW, Park HY, Kim Y, Park GY, Im S. Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study. Neurogastroenterol Motil 2021;33:e13953.
69. Vasant DH, Payton A, Mistry S, Thompson DG, Hamdy S. The val66met polymorphism of brain-derived neurotrophic factor is associated with human esophageal hypersensitivity. Neurogastroenterol Motil 2013;25:162-e85.
70. Essa H, Vasant D, Raginis-zborowska A, Payton A, Michou E, Hamdy S. PTU-182 Can response to pharyngeal stimulation in dysphagic stroke be predicted by bdnf genetic polymorphisms? Gut 2015;64:A143.1-A143.
71. Mentz H, Horan M, Payton A, Ollier W, Pendleton N, Hamdy S. Homozygosity in the ApoE 4 polymorphism is associated with dysphagic symptoms in older adults. Dis Esophagus 2015;28:97-103.
72. Raginis-Zborowska A, Mekli K, Payton A, Ollier W, Hamdy S, Pendleton N. Genetic determinants of swallowing impairments among community dwelling older population. Exp Gerontol 2015;69:196-201.
73. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003;2002:CD003735.
74. Schuh MJ, Crosby S. Chronic anticholinergic toxicity discovered in a pharmacogenomics, polypharmacy patient. Sr Care Pharm 2021;36:304-10.
75. Eum S, Hill SK, Alliey-Rodriguez N, et al. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology 2021;46:1802-10.
76. Kersten H, Wyller TB, Molden E. Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs. Ther Drug Monit 2014;36:125-30.
77. Gurocak S, Konac E, Ure I, et al. The impact of gene polymorphisms on the success of anticholinergic treatment in children with overactive bladder. Dis Markers 2015;2015:732686.
78. Villa A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag 2015;11:45-51.
79. Endo T, Nakajima M, Fukami T, et al. Genetic polymorphisms of CYP2A6 affect the in vivo pharmacokinetics of pilocarpine. Pharmacogenet Genomics 2008;18:761-72.
80. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013;5:CD002095.
81. Addington WR, Stephens RE, Gilliland K, Miller SP. Tartaric acid-induced cough and the superior laryngeal nerve evoked potential. Am J Phys Med Rehabil 1998;77:523-6.
82. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 2013;15:119-31.
83. Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol 2018;14:447-60.
84. Harris DM, Stancampiano FF, Burton MC, et al. Use of pharmacogenomics to guide proton pump inhibitor therapy in clinical practice. Dig Dis Sci 2021;66:4120-7.
85. Patial RK. Baclofen in the treatment of intractable hiccups. J Assoc Physic India 2002;50:1312-3.
86. McLaughlin MJ, He Y, Brunstrom-Hernandez J, et al. Pharmacogenomic variability of oral baclofen clearance and clinical response in children with cerebral palsy. PMR 2018;10:235-43.
